✍ Scribed by S. Rudnicki; F. Vriesendorp; C. L. Koski; Dr. R. F. Mayer
No coin nor oath required. For personal study only.
Nerve conduction studies (NCS) and antiperipheral nerve myelin antibody (A-PNM Ab) titers were measured serially in 29 patients with Guillain-Barr6 syndrome (GBS), of whom 21 were treated with plasmapheresis. Data were obtained from 3 to 6 days until 1 to 2 years after onset of symptoms. Within 3 to 6 days, mean NCS were abnormal. They improved some by 1 week and became maximally abnormal by 4 to 8 weeks, during which time A-PNM Ab fell to low levels. In 5 patients plasmapheresed, A-PNM Ab fell and then increased at 4 to 8 weeks, followed by significant deterioration of NCS (P = 0.01) compared with those without antibody rebound at 18 weeks. These results suggest that, in monophasic GBS, there may be two mechanisms of conduction dysfunction such as early paranodal retraction and later demyelination. In some patients plasmapheresed, A-PNM Ab may rebound associated with further conduction dysfunction. These patients may benefit from further plasmapheresis.
📜 SIMILAR VOLUMES
To clarify the question of whether Guillain-Barre ´syndrome (GBS) patients treated with intravenous immune globulin (IVIG) relapse at a higher frequency than those treated with plasma exchange (PE), 54 patients with GBS were studied retrospectively. A higher frequency of relapses was noted in the PE
Serum from 20 patients with Guillain-Barr6 syndrome (GBS), 10 healthy controls and 10 patients with recent cytomegalovirus, Epstein-Barr virus, or Campylobacter jejunilcoli infections was injected into rat sciatic nerve. The 20 GBS patients consisted of 2 groups of 10 patients with different electro
## IMMUNE MODULATION AND PLASMA EXCHANGE Transferable Serum Factors In 1971, Stuart Cook and colleagues reported that sera from 26 of 31 patients with Guillain-Barre syndrome caused complement-dependent demyelination of living